Drugs / AST2303
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06955988 | Mar 2025 → Dec 2026 expected | non-small cell lung carcinoma | Allist Pharmaceuticals, Inc. | Recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2024-09-25 | Abbisko Therapeutics Co, Ltd | Regulatory Clinical Trial of Next-Generation EGFR Inhibitor ABK3376, Co-developed by Abbisko Therapeutics and Allist Pharmaceuticals, Approved by NMPA abbisko.com ↗ |
All press releases naming this drug 2 releases
| Date | Issuer | Release |
|---|---|---|
| 2024-09-25 | Abbisko Therapeutics Co, Ltd | Clinical Trial of Next-Generation EGFR Inhibitor ABK3376, Co-developed by Abbisko Therapeutics and Allist Pharmaceuticals, Approved by NMPA abbisko.com ↗ |
| 2023-03-01 | Abbisko Therapeutics Co, Ltd | Abbisko Therapeutics Announces an Out-License Agreement with Allist for ABK3376 abbisko.com ↗ |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | AST2303 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06955988 ↗ |
| Known as | ABK3376 | “AST2303 Tablets (ABK3376 Tablets)” NCT06955988 ↗ |
| Route | Oral | “25mg, oral on an empty stomach” NCT06955988 ↗ |